CDH1 and breast cancer: Significant associations of reduced E-Cadherin expression with poor outcome in invasive breast cancer [10–12, 53–57], triple receptor negativity in breast cancer [58], poor outcome and unfavorable tumor phenotype in colorectal cancer [29, 30, 59, 60], and adverse features in prostate cancer [13, 14] have been reported by various other investigators.